Manufacturer of Vandetanib

Vandetanib (Vandetanib) is a kinase inhibitor indicated for the treatment of patients with symptomatic or progressive medullary thyroid cancer who have unresectable (inoperable) locally advanced or metastatic disease. Due to treatment-related risks, the use of vandetanib should be carefully considered in patients with indolent, asymptomatic, or slowly progressive disease.

Vandertanib was originally developed and produced byAstraZeneca (AstraZeneca). It is the only drug approved by the U.S. Food and Drug Administration (FDA) specifically for patients with advanced medullary thyroid cancer. It is also the first therapeutic drug developed by AstraZeneca and marketed with orphan drug designation in the United States. The approval of vandetanib was based on results from the ZETA study, in which patients randomized to vandetanib demonstrated a statistically significant improvement in progression-free survival (PFS) compared with patients randomized to placebo. This difference reflected a 65% reduction in the risk of disease progression, which was at least 22.6 months in the vandetanib group. In the primary PFS analysis, no significant difference in overall survival was found. QT prolongation, torsade de pointes, and sudden death are included in the boxed warning for vandetanib, and the most common adverse drug reactions (>20%) are diarrhea, rash, acne, nausea, hypertension, headache, fatigue, decreased appetite, and abdominal pain.

The original drug of vandetanib has not yet been launched in China, so it is not included in the medical insurance. The original drug of Vandetanib listed overseas may cost more than 30,000 yuan per box of 300mg*30 tablets (the price may fluctuate due to exchange rates). Currently, there is no generic version of Vandetanib on the market. For more drug information and specific prices, please consult the medical consultant of Yaode.